In 2021, our work published in Science identified actionable neoantigens from major cancer driver genes such as TP53 and KRAS, defining a new paradigm for precision and personalized cancer immunotherapy.
Neoantigen Immunotherapy Breakthroughs Enabled by the Valid-NEO® Platform
In 2021, two landmark studies published in Science and Science Immunology demonstrated that neoantigens derived from cancer driver mutations can serve as highly precise therapeutic targets for next-generation immunotherapies. These studies provided compelling validation of the emerging paradigm that mutation-derived peptides can be directly targeted to eliminate cancer cells.
Both studies leveraged technologies developed by Qing Wang and colleagues for direct detection and validation of neoantigens, forming the basis of the Valid-NEO® platform, one of the foundational technologies later incorporated into Complete Omics.
The first study, “Targeting a neoantigen derived from a common TP53 mutation,” demonstrated that T cells could be engineered to recognize a peptide derived from mutant TP53—one of the most frequently altered tumor suppressor genes in human cancers. By targeting this mutation-derived peptide, immune cells could selectively attack tumor cells carrying the mutation while sparing normal tissues.
The second study, “Bispecific antibodies targeting mutant RAS neoantigens,” showed that neoantigens derived from KRAS driver mutations could be targeted using engineered bispecific antibodies that recruit immune cells to tumor cells presenting these mutation-specific peptides.
Together, these studies represented a major milestone for precision oncology. They showed that shared cancer driver mutations across many patients can generate actionable neoantigens, opening new opportunities for highly targeted immunotherapies.
The Role of the Valid-NEO® Platform
A central challenge in neoantigen research has been determining which predicted mutation-derived peptides are actually produced and presented by tumor cells. Most discovery pipelines rely heavily on genomic sequencing and computational prediction, which often generate large numbers of theoretical candidates but lack experimental confirmation.
The Valid-NEO® platform was developed to address this critical gap.
By integrating genomic mutation data with highly sensitive targeted proteomics assays, Valid-NEO® enables the direct detection and quantitative validation of mutation-derived peptides, allowing researchers to confirm whether predicted neoantigens truly exist within biological samples.
This capability transforms neoantigen discovery from a purely computational prediction problem into an experimentally validated molecular measurement process.
Enabling the Next Generation of Precision Immunotherapy
The 2021 publications provided strong clinical and therapeutic validation of this concept. By targeting neoantigens derived from major cancer driver mutations such as TP53 and KRAS, the studies demonstrated that mutation-derived peptides can serve as highly specific therapeutic targets across multiple cancer types.
These findings helped catalyze growing global interest in neoantigen-based immunotherapies, including:
- engineered T-cell therapies
- bispecific antibodies
- personalized cancer vaccines
- mutation-specific immune targeting strategies
From Valid-NEO® to Complete360®
The success of these studies reinforced a central scientific principle behind Complete Omics:
Precision immunotherapy depends on precise molecular measurement.
The Valid-NEO® platform established one of the earliest technologies for experimentally validating neoantigens derived from cancer mutations. These capabilities later became part of the broader technological ecosystem developed by Complete Omics, including the Complete360® ultra-deep clinical proteomics platform, which enables large-scale measurement of thousands of proteins and peptides across clinical samples.
Together, these platforms aim to provide the molecular measurement infrastructure required to translate genomic discoveries into actionable therapeutic targets across human disease.
At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr.